Gene Silencing Therapy (SOT)

What Is Gene Silencing Therapy?

Gene silencing therapy is based on RNA interference (RNAi), a natural process your cells use to regulate which genes are switched on. In RNAi, short RNA molecules bind to a matching messenger RNA (mRNA) and prevent it from being translated into protein, effectively silencing the expression of a targeted gene. This mechanism was discovered by Andrew Fire and Craig Mello, who received the 2006 Nobel Prize in Physiology or Medicine for the work,¹ and it has since become one of the most actively developed strategies in modern medicine.

In the SOT approach, a laboratory analyzes a patient’s blood sample to identify a genetic sequence associated with the targeted pathogen, then develops a patient-specific oligonucleotide intended to interfere with that sequence. Because the preparation is made from the individual’s own biological material and aimed at a defined target, it is designed to be highly personalized rather than one-size-fits-all.

Gene Silencing Therapy and Lyme Disease

Lyme disease is the most common tick-borne infection in North America, caused by Borrelia burgdorferi, and most people recover with timely antibiotic treatment. For a meaningful subset, however, symptoms such as fatigue, pain, and cognitive difficulty persist. A review of Lyme disease notes that this has driven active interest in new and emerging approaches,⁴ and a mechanistic review reports that post-treatment Lyme disease syndrome (PTLDS) affects roughly 10 to 20% of treated patients through mechanisms that are still being understood.⁵ For people in this situation, who often feel they have run out of conventional options, the personalized and targeted nature of gene silencing therapy is part of what makes it an area of interest. At Longevity Centers of America, it is considered within a Lyme-literate, physician-guided evaluation that looks at the whole person.

What to Expect

If you are considering gene silencing therapy, understanding the process can help you make an informed decision. As carried out under the supervision of a qualified practitioner, the process generally follows several steps:

Safety and Important Considerations

Like all medical approaches, gene silencing therapy should be provided by qualified healthcare professionals after appropriate screening. Important considerations include:

• Professional administration: the approach should only be carried out by licensed medical providers.
• Medical screening: a thorough evaluation determines whether the approach is appropriate for you, as not everyone is a candidate.
• Contraindications: it is generally not appropriate during pregnancy or after a recent blood transfusion, and age-based restrictions apply.
• Concurrent care: certain other treatments or conditions may affect suitability and should be reviewed with your provider.

Take the Next Step

Gene silencing therapy reflects how personalized and RNA-based approaches are expanding the options explored in longevity and integrative medicine. If you are living with chronic or persistent Lyme symptoms and want to understand whether an investigational, personalized approach like gene silencing therapy may have a place in your plan, the most important step is a conversation with a qualified physician who can review your history and goals with you. Contact us today to learn more or to schedule a consultation.

Individual results may vary. These statements have not been evaluated by the FDA. Gene silencing therapy (SOT) is an investigational approach and has not been approved or cleared by the U.S. Food and Drug Administration to diagnose, prevent, or treat Lyme disease or any other condition. It is offered as part of an individualized, physician-supervised plan and is not a substitute for standard, evidence-based medical care. All therapies are administered by licensed healthcare professionals. Consult with your healthcare provider before beginning any new wellness protocol.